Clinical Trials Browser

Unknown × fludarabine × Gynecologic × Clear all

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Phase 1 Unknown

12 enrolled

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT03814447 2021-08-10

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Phase EARLY_PHASE1 Unknown

10 enrolled

Gynecologic

Ovarian Neoplasms

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03799913 2019-04-10

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Phase EARLY_PHASE1 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03412526 2019-04-04

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Phase 2 Unknown

15 enrolled

Gynecologic

Ovarian Neoplasms

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

Phase 1 Unknown

9 enrolled

DermatologicGastrointestinalGynecologicHead & NeckSarcoma

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03335241 2017-11-13

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Phase 2 Unknown

140 enrolled

Gynecologic

Ovarian Neoplasms

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Clinical Trials

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Investigator Initiated Phase 1 Study of TBI-1301

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies